Novartis's big bet on sickle cell disease struggles to reach Kenya

Pharma giants are pouring money into new therapies for sickle cell disease but in Kenya, patients struggle to access a decades-old drug.

Related Keywords

Kenya ,Denmark ,Germany ,Kisumu ,Nyanza ,California ,United States ,Nairobi ,Nairobi Area ,Switzerland ,Mathare ,Kenya General ,Kenyan ,Kenyans ,Danish ,German ,Swiss ,Racey Muchilwa ,Moses Apela ,Shadrack Otenyo ,Bernard Awuonda ,Jaramogi Oginga Odinga ,Selina Olwanda ,Gladwell Gathecha ,Elliott Vichinsky ,Emaculate Achieng ,Pfizer ,Children Sickle Cell Foundation ,Drug Administration ,Kenyan Ministry Of Health ,Gates Foundation ,Novartis ,Novo Nordisk ,Series Access ,Kenya This ,Sickle Cell ,South Asia ,North Africa ,Global Blood Therapeutics ,Forma Therapeutics ,Children Sickle Cell Foundationexternal ,German Doctors ,Kisumu County ,Jaramogi Oginga Odinga Teaching ,Kenyan Ministry ,Saharan Africa ,Bluebird Bio ,Beta Thalassemia ,Health ,Health Treatment ,Therapy ,Multinationals ,